Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals has successfully dosed the first patient in a Phase IB/II clinical trial for its cancer treatment combination of IMM2510 and IMM01, marking a significant milestone in cancer immunotherapy. This development could enhance the company’s industry positioning by showcasing its innovative approach to cancer treatment, potentially impacting stakeholders positively.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on innovative cancer immunotherapy. The company develops bispecific molecules and fusion proteins targeting cancer cells, with a market focus on the Greater China region and global intellectual property rights for its core products.
Average Trading Volume: 3,683,686
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.5B
For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.